Begin main content

fluticasone furoate/vilanterol

Last Updated: December 14, 2017
Result type: Reports
Project Number: SR0524-000
Product Line: Common Drug Review

Generic Name: fluticasone furoate/vilanterol

Brand Name: Breo Ellipta

Manufacturer: GlaxoSmithKline Inc.

Indications: COPD

Submission Type: Resubmission

Project Status: Withdrawn

Biosimilar: No

Key Milestones2

Call for patient input posted3May 31, 2017
Patient group input closed3July 20, 2017

- Patient input submission received

Patient input summary sent for review to patient input groupsJuly 25, 2017
Patient group comments on input summary closedAugust 01, 2017

- Patient input summary feedback received

Submission receivedJune 28, 2017
Submission accepted for reviewJuly 13, 2017
Review initiatedJuly 14, 2017
Draft CDR review report(s) sent to applicantSeptember 28, 2017
Comments from applicant on draft CDR review report(s) receivedOctober 10, 2017
Redaction requests from applicant on draft CDR review report(s) receivedOctober 17, 2017
CDR review team's comments on draft CDR review report(s) sent to applicantNovember 03, 2017

- Voluntarily withdrawn by the manufacturer on 2017-Nov-09

  1. Refer to Appendix 1 of the Procedure for the CADTH Common Drug Review for details regarding CDR application fee schedules.
  2. Please refer to the Procedure for the CADTH Common Drug Review for complete details regarding the CDR process and targeted time frames for key milestones.
  3. The call for patient group input is posted 20 business days in advance of the applicant's anticipated date of filing the CDR application. Patient groups have a total of 35 business days for preparing and submitting patient input.
  4. The embargoed CDEC recommendation is held in confidence by all stakeholders and not acted upon until after CADTH has issued the notice of CDEC Final Recommendation.The applicant may make a request for reconsideration or resubmission based on reduced price during the embargo period, and the drug plans may make a request for clarification, as applicable (see section 8 of the Procedure for the CADTH Common Drug Review).
  5. The timing for posting the CDEC Final Recommendation and CDR review report(s) depends on several factors including the need for consultation with the applicant regarding redaction issues.
  6. The time frame required to address a request for clarification at the drug plans' request or request for reconsideration at the applicant's request depends on the amount of work required to address the request and the available dates for CDEC meetings.


copd, pulmonary disease, chronic obstructive, Chronic obstructive pulmonary disease; COPD